In 2013, anti‐cytosolic 5′‐nucleotidase 1A (NT5C1A) antibody was detected in the sera of patients with IBM and recognized as a potential diagnostic marker for IBM.2, 3. This evidence concerns the gene NT5C1A and inclusion body myositis.